Published in Vaccine Weekly, August 16th, 2006
"Cancer patients develop antitumor immune responses, both humoral and cellular, against antigens expressed by their tumors. Low-throughput antigen cloning has been used to identify a number of immunogenic tumor antigens, but this process has limited utility for diagnostics or therapeutic vaccines," according to scientists in the United States.
"A novel approach to the identification of diagnostic antigens that utilizes a combination...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.